A. Curnock

发表

LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells.

K. Knox, A. Curnock, Adam P. Curnock, 1998, Cellular immunology.

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors

Emma L Henderson, J. Kumaran, L. Bawden, 2021, JCI insight.

Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis.

L. Settimo, A. Tanner, H. Twin, 2019, ACS medicinal chemistry letters.

Selective protein kinase Cθ (PKCθ) inhibitors for the treatment of autoimmune diseases.

J. Jiménez, A. Curnock, P. Weber, 2014, Biochemical Society transactions.

Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs.

R. Williamson, D. Moss, A. Curnock, 1997, The Journal of pharmacology and experimental therapeutics.

Optimal Chemotactic Responses of Leukemic T Cells to Stromal Cell-Derived Factor-1 Requires the Activation of Both Class IA and IB Phosphoinositide 3-Kinases1

S. Ward, K. Wright, Y. Sotsios, 2003, The Journal of Immunology.

IB Phosphoinositide 3-Kinases Requires the Activation of Both Class IA and T Cells to Stromal Cell-Derived Factor-1 Optimal Chemotactic Responses of Leukemic

S. Ward, K. Wright, Y. Sotsios, 2003 .

Inhibition of stimulated Jurkat cell adenosine 3',5'-cyclic monophosphate synthesis by the immunomodulatory compound HR325.

R. Williamson, A. Curnock, T. Thomson, 2001, Biochemical pharmacology.

Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.

A. Tanner, H. Twin, J. Jiménez, 2011, Journal of medicinal chemistry.

Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.

R. Williamson, T. Hercend, J. Bruneau, 1996, Transplantation proceedings.

Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound (*)

P. Morand, R. Williamson, T. Hercend, 1995, The Journal of Biological Chemistry.

Chemokine signalling: pivoting around multiple phosphoinositide 3‐kinases

S. Ward, Adam P. Curnock, Marisa K. Logan, 2002, Immunology.

Identification and characterization of Nanobodies targeting the EphA4 receptor

B. de Strooper, W. Robberecht, P. van Damme, 2017, The Journal of Biological Chemistry.

Identification and characterization of Nanobodies targeting the EphA 4 receptor

B. Strooper, W. Robberecht, L. Chávez-Gutiérrez, 2017 .

Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases.

L. Settimo, A. Tanner, Jaclyn L Henderson, 2013, Journal of medicinal chemistry.

Development and characterisation of tetracycline-regulated phosphoinositide 3-kinase mutants: assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling.

S. Ward, A. Curnock, 2003, Journal of immunological methods.

Structure-based optimization of aminopyridines as PKCθ inhibitors.

L. Settimo, A. Tanner, J. Jiménez, 2012, Bioorganic & medicinal chemistry letters.

Assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling: use of dominant negative mutants controlled by a tetracycline-regulated gene expression system.

S. Ward, Y. Sotsios, A. Curnock, 2004, Methods in molecular biology.